RxDoctor Payments Data

Grace Thomas, MD

Endocrinology, Diabetes & Metabolism · North Easton, MANPI 1114275393

Payments from drug & device makers

$904in general payments, 2019–2025

Across 20 payments — averaging $45.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$364
  • Medtronic$326
  • AbbVie$114
  • Bayer$23
  • Novo Nordisk$21
  • Sequel Med Tech, LLC$20
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$37842%
  • Education$52658%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$364
Medtronic(2 entities)4$326
AbbVie5$114
Bayer1$23
Novo Nordisk1$21
Sequel Med Tech, LLC1$20
Esperion Therapeutics, Inc.1$19
Lilly USA, LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904 in reported general payments places this provider in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$39,275
Medicare patients
181
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide155$227,787
MounjaroTirzepatide103$114,206
TrulicityDulaglutide75$78,583
JardianceEmpagliflozin40$38,410
FarxigaDapagliflozin Propanediol21$15,741
RybelsusSemaglutide12$14,147
Tresiba Flextouch U-100Insulin Degludec13$8,839
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,401
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp15$4,298
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,944
Ultra-Fine Short Pen NeedlePen Needle, Diabetic42$2,522
Nano 2nd Gen Pen NeedlePen Needle, Diabetic22$1,910
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,826
Novolog FlexpenInsulin Aspart11$1,592
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic14$1,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$21$241,934167 claims
Lilly USA, LLCMounjaro, Trulicity$18$192,789178 claims
AbbVieSynthroid$114$82816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

Other endocrinology, diabetes & metabolism in North Easton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →